Linical Co

Linical Co R&D / Revenue

R&D to Revenue Ratio of Linical Co (2183.T) as of Oct 18, 2026.

R&D / Revenue

0.00

Last updated:

R&D to Revenue Ratio of Linical Co is 2026 0.00 . R&D to Revenue Ratio of Linical Co was 2025 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linical Co Stock analysis

What does Linical Co do? Linical Co Ltd provides pharmaceutical contract research services including consulting, monitoring, and quality control to pharmaceutical companies. Headquartered in Osaka, Japan, the company employs 759 people. It went public on October 27, 2008. The company operates in two segments: CRO services for phase II and III drug development monitoring and quality management, and pharmaceutical sales support for medical institutions in the downstream market. Linical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linical Co stock

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Linical Co since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Linical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Linical Co

All Key Metrics — Linical Co